EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)

Luca Gentile, Igor Diemberger iD, Violaine Plante-Bordeneuve, Anna Mazzeo, Amir Dori, Marco Luigetti iD, Andrea Di Paolantonio, Angela Dispenzieri, Martha Grogan, Márcia Waddington Cruz, David Adams, Jocelyn Inamo und 6 weitere

PLOS ONE · 19.01.2024 · 19 (1) · e0292435

DOI: 10.1371/journal.pone.0292435 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift PLOS ONE, online erschienen am 19.01.2024. Verfasst von Luca Gentile und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Università of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transthyretin amyloidosis (ATTR amyloidosis) is a progressive, multi-systemic disease with wild-type (ATTRwt) and hereditary (ATTRv) forms. Over 130 variants associated with ATTRv amyloidosis have been identified, although little is known about the majority of these genotypes. This analysis examined phenotypic characteristics of symptomatic patients with ATTRv amyloidosis enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS) with four less frequently reported pathogenic genotypes: F64L (c.250T>C, p.F84L), I68L (c.262A>T, p.I88L), I107V (c.379A>G; p.I127V), and S77Y (c.290C>A; p.S97Y). THAOS is the largest ongoing, global, longitudinal observational study of patients with ATTR amyloidosis, including both ATTRwt and ATTRv amyloidosis. This analysis describes the baseline demographic and clinical characteristics of untreated symptomatic patients with the F64L, I68L, I107V, or S77Y genotypes at enrollment in THAOS (data cutoff date: January 4, 2022). There were 141 symptomatic patients with F64L (n = 46), I68L (n = 45), I107V (n = 21), or S77Y (n = 29) variants at the data cutoff. Most patients were male and median age at enrollment was in the sixth decade for S77Y patients and the seventh decade for the others. A predominantly neurologic phenotype was associated with F64L, I107V, and S77Y genotypes, whereas patients with the I68L genotype presented with more pronounced cardiac involvement. However, a mixed phenotype was also reported in a considerable proportion of patients in each variant subgroup. This analysis from THAOS represents the largest study of ATTRv symptomatic patients with the F64L, I68L, I107V, and S77Y genotypes. These data add to the limited knowledge on the clinical profile of patients with specific ATTRv variants and emphasize the importance of comprehensive assessment of all patients. Trial registration ClinicalTrials.gov: NCT00628745 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialFemaleHumansMaleGenotypePhenotypePrealbuminSurveys and QuestionnairesMiddle AgedAged

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Università of Messina, Messina, Italy.
  • University of Bologna, Department of Medical and Surgical Sciences, Bologna, Italy.
  • Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Hopital Henri Mondor, Assistance Publique-Hopitaux de Paris, East Paris-Créteil University, Créteil, France.
  • Department of Neurology, Sheba Medical Center, Ramat Gan, and Tel-Aviv University, Tel-Aviv, Israel.
  • Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

ORCID-Profile: Igor Diemberger, Marco Luigetti

Förderung

  • Pfizer

Zitieren

APA

Gentile, L., Diemberger, I., Plante-Bordeneuve, V., Mazzeo, A., Dori, A., Luigetti, M., Di Paolantonio, A., Dispenzieri, A., Grogan, M., Waddington Cruz, M., Adams, D., Inamo, J., Kristen, A. V., Lino Cirami, C., Chapman, D., Gupta, P., Glass, O., & Amass, L. (2024). Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS). PLOS ONE, 19(1), e0292435. https://doi.org/10.1371/journal.pone.0292435

Vancouver

Gentile L, Diemberger I, Plante-Bordeneuve V, Mazzeo A, Dori A, Luigetti M, et al. Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS). PLOS ONE. 2024;19(1):e0292435. doi:10.1371/journal.pone.0292435

BibTeX
@article{Gentile2024,
  author = {Gentile, Luca and Diemberger, Igor and Plante-Bordeneuve, Violaine and Mazzeo, Anna and Dori, Amir and Luigetti, Marco and Di Paolantonio, Andrea and Dispenzieri, Angela and Grogan, Martha and Waddington Cruz, Márcia and Adams, David and Inamo, Jocelyn and Kristen, Arnt V and Lino Cirami, Calogero and Chapman, Doug and Gupta, Pritam and Glass, Oliver and Amass, Leslie},
  title = {Phenotypic characteristics of F64L, I68L, I107V, and S77Y ATTRv genotypes from the Transthyretin Amyloidosis Outcomes Survey (THAOS)},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {1},
  pages = {e0292435},
  doi = {10.1371/journal.pone.0292435}
}
Kostenlos starten →